This site is intended for US healthcare professionals

Congresses

The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

ENCORE POSTER
Baseline Demographics and Clinical Characteristics From OASIS: Observational Study of Long-Acting Injectables in Schizophrenia
Author(s):

Lauren N. Strand,1 Michael J. Doane,1 Christina Arevalo,1 James A. McGrory,1 Peter J. Weiden,2 Eric D. Achtyes,3 Phillip D. Harvey,4 John M. Kane,5 Stephen R. Saklad,6 Jeffrey Trotter,7 Dawn I. Velligan8

1Alkermes, Inc., Waltham, MA, USA; 2Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA; 3Western Michigan University Homer Stryker M.D. School of Medicine, Kalamazoo, MI, USA; 4University of Miami Miller School of Medicine, Miami, FL, USA; 5The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA; 6The University of Texas at Austin, College of Pharmacy, Division of Pharmacotherapy, UT Health Science Center San Antonio, San Antonio, TX, USA; 7Worldwide Clinical Trials, Research Triangle, NC, USA; 8UT Health Science Center at San Antonio, San Antonio, TX, USA

Content available until 11/09/2025